Patent US4542129A successfully refreshed from Google Patents.
US4542129A
Expired / Lapsed
US
⏱️ 0.0 years remaining
DHEA Formulations and methods for treating dry skin
Assignee: Individual
•
Filing: 1985-01-24
•
Granted: 1985-09-17
•
Expires: 2005-01-24
Abstract
Abstract Topical formulations for treating dry skin with dehydroepiandrosterone (DHEA) may contain a keratolytic agent to counteract the formation of acne-like skin lesions without diminishing the effectiveness of DHEA in increasing sebum production. The keratolytic agent may be a hydroxybenzoic acid, alpha-hydroxycarboxylic acid or urea, with salicylic acid being preferred. The DHEA and keratolytic agent may be formulated in a non-toxic, dermatologically acceptable vehicle including tinctures, creams, ointments, gels and lotions.
Inventors
- 👤 Norman Orentreich
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 20:19
CPC Classifications
A; A61; A61Q; A61Q19/00; A61Q19/007; A61K; A61K31/00; A61K31/56; A61K31/565; A61K8/00; A61K8/18; A61K8/30; A61K8/63
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
61 words
A topical composition for treating dry skin in a patient comprising: a. dehydroepiandrosterone and/or a pharmaceutically acceptable, therapeutically effective derivative thereof in an amount effective to increase sebum production; b. a keratolytic agent in an amount sufficient to counteract the formation of acne-like skin lesions without diminishing the effectineness of dehydroepiandrosterone or its derivative; and c. a non-toxic, dermatologically acceptable vehicle.
Claim 2
Dependent Claim
61 words
A topical composition for treating dry skin in a patient comprising: a. dehydroepiandrosterone and/or a pharmaceutically acceptable, therapeutically effective derivative thereof in an amount effective to increase sebum production; b. a keratolytic agent in an amount sufficient to counteract the formation of acne-like skin lesions without diminishing the effectineness of dehydroepiandrosterone or its derivative; and c. a non-toxic, dermatologically acceptable vehicle.
Claim 3
Dependent Claim
23 words
A composition according to claim 1 wherein said keratolytic agent is selected from the group consisting of hydroxybenzoic acids, alpha-hydroxycarboxylic acids and urea.
Claim 4
Dependent Claim
23 words
A composition according to claim 2 wherein said alpha-hydroxycarboxylic acid is selected from the group consisting of glycolic, tartaric, lactic and mandelic acids.
Claim 5
Dependent Claim
25 words
A composition according to claim 3 wherein said keratolytic agent is present in an amount of about 0.1 to 10 weight percent of the composition.
Claim 6
Dependent Claim
13 words
A composition according to claim 2 wherein said keratolytic agent is salicylic acid.
Claim 7
Dependent Claim
25 words
A composition according to claim 5 wherein said salicylic acid is present in an amount of about 0.1 to 2 weight percent of the composition.
Claim 8
Dependent Claim
27 words
A composition according to claim 1 wherein said dehydroepiandrosterone and/or derivative thereof is present in an amount of about 0.01 to 1.0 weight percent of the composition.
Claim 9
Dependent Claim
39 words
A composition according to claim 1 wherein dehydroepiandrosterone free alcohol is present in an amount of about 1.0 weight percent and said keratolytic agent is salicylic acid present in an amount of about 1.0 weight percent of the composition.
Claim 10
Dependent Claim
22 words
A composition according to claim 1 wherein said vehicle is selected from the group consisting of tinctures, creams, ointments, gels and lotions.
Claim 11
Independent Claim
65 words
A method of treating dry skin in a patient which comprises topically administering to the area of dry skin in the patient a composition comprising (a) an effective amount of dehydroepiandrosterone and/or a pharmaceutically acceptable, therapeutically effective derivative thereof and (b) a keratolytic agent in an amount sufficient to counteract the formation of acne-like skin lesions without diminishing the effectiveness of dehydroepiandrosterone or its derivative.
Claim 12
Independent Claim
65 words
A method of treating dry skin in a patient which comprises topically administering to the area of dry skin in the patient a composition comprising (a) an effective amount of dehydroepiandrosterone and/or a pharmaceutically acceptable, therapeutically effective derivative thereof and (b) a keratolytic agent in an amount sufficient to counteract the formation of acne-like skin lesions without diminishing the effectiveness of dehydroepiandrosterone or its derivative.
Claim 13
Dependent Claim
13 words
A method according to claim 10 wherein said keratolytic agent is salicylic acid.
Claim 14
Dependent Claim
20 words
A method according to claim 10 wherein said salicylic acid comprises about 0.1 to 2 weight percent of said composition.
Claim 15
Dependent Claim
27 words
A method according to claim 10 wherein said keratolytic agent is an alpha-hydroxycarboxylic acid in an amount of about 0.1 to 10 weight percent of the composition.
Claim 16
Dependent Claim
15 words
A method according to claim 10 wherein said patient has a genetic tendency for acne.
Claim 17
Dependent Claim
20 words
A method according to claim 10 wherein said composition contains about 0.01 to 1 weight percent dehydroepiandrosterone and/or derivative thereof.
Claim 18
Dependent Claim
29 words
A method according to claim 10 wherein said composition is administered in a non-toxic, dermatologically acceptable vehicle selected from the group consisting of tinctures, creams, ointments, gels and lotions.
References Cited (Backward Citations)
US3162631A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-09-16 | 1989-03-18 | 1989-09-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-09-16 | 1993-03-18 | 1993-09-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-09-16 | 1997-03-18 | 1997-09-17 | $7700.00 | Window Closed / Lapsed |